Back

Successful treatment of pulmonary hypertension and right heart failure by antibody-based functional blocking of the extra-domain A of fibronectin in a preclinical animal model

25 August 2023 (15:15 - 16:00)
Organised by: Logo
Congress Presentation Part of: Improving outcomes in heart failure: bench to bedside Cardiovascular Pharmacotherapy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Professor Marcus Franz

Cardiovascular Center Rotenburg an der Fulda, Rotenburg an der Fulda (Germany)

8 More presentations in this session

Presentation thumbnail
Are heart failure patients with mildly reduced ejection fraction treated according to current international guidelines?
Doctor T. Schupp (Mannheim, DE)
Abstract Slides Video
Presentation thumbnail
The power of optimal medical therapy in heart failure with secondary mitral regurgitation
Unknown A. Borrellas Martin (Barcelona, ES)
Abstract Slides Video
Presentation thumbnail
Prescribing trends of sodium-glucose cotransporter 2 Inhibitors in patients with heart failure with preserved, mildly reduced and reduced ejection fraction
Doctor F. Hofer (Vienna, AT)
Abstract Slides Video
Presentation thumbnail
Effects of colchicine treatment after myocardial infarction on top of standard therapy: evidence from a preclinical study
Doctor A. Aimo (Pisa, IT)
Abstract Slides Video
Presentation thumbnail
Acute over-additive natriuretic effects by a combination of finerenone and SGLT2 inhibition in rats with an activated renin-angiotensin-aldosterone system: a mechanistic basis for clinical outcomes?
Doctor P. Kolkhof (Wuppertal, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Improving outcomes in heart failure: bench to bedside

The Event

Event poster

ESC Congress 2023

25 August 2023 15:15 CET
You may be interested in
thumbnail
Congress Session
Molecular approaches to the treatment of pulmonary hypertension
thumbnail
Congress Session
Pathobiology of pulmonary hypertension
thumbnail
Congress Presentation
Targeting alpha 5 beta 1 integrin as a therapeutic strategy to combat right ventricular dysfunction in pulmonary arterial hypertension

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources